National Institute for Health and Clinical Excellence (NICE)
NICE signs up to join the GetReal Institute
NICE’s ambition complements the GetReal Institute’s core mission to facilitate the adoption and implementation of real-world evidence in health care decision-making.
NICE yesterday (Wednesday 28 April, 2021) announced it will join with nine other organisations to form the GetReal Institute as a founding member.
NICE’s new five-year strategy sets out how the organisation wants to have a leadership role in data, research and science. The strategy aim will involve driving the research agenda, using real world data to resolve gaps in knowledge and drive forward access to innovations for patients.
NICE’s ambition for this area complements the GetReal Institute’s core mission to facilitate the adoption and implementation of real-world evidence (RWE) in health care decision-making in Europe.
Joining NICE, the following organisations have expressed their intention to sign up as founding members (pending finalisation and execution of membership agreements):
- Clinical Practice Research Datalink (CPRD) (UK)
- Eli Lilly and Company
- Hoffmann-La Roche
- International Alliance of Patients’ Organizations (IAPO)
- Janssen, Pharmaceutical Companies of Johnson & Johnson
- National Institute for Health and Care Excellence (NICE) (UK)
- Norwegian Medicines Agency (NoMA)
- University Medical Center Utrecht (UMCU)
Additional participating organisations will be announced in due course.
The GetReal Institute will initially prioritise efforts in three areas:
- Reducing barriers to using data that is generated in routine clinical practice in health care decision making, including addressing challenges with real world data discoverability, quality, and accessibility
- Bridging the gap between RWE and conventional randomised controlled trial (RCT) approaches through, for example, incorporation of “real world” elements in RCT design and implementation, use of real world data-based external comparator arms in clinical trials, and use of non-interventional study designs
- Addressing the evidence needs of "downstream" decision-makers -- HTA bodies, payers, clinical guideline developers, clinicians, and patients -- whose perspectives and decision contexts are as important as those of regulatory agencies.
Dr Felix Greaves, director of Science, Evidence and Analytics at NICE, yesterday said:
“NICE is highly regarded around the globe and is seen as a world leader in health technology evaluation and the development of clinical guidelines.
“Our involvement in the GetReal Institute fits very well with our newly launched five-year strategy and will benefit work in the Science, Evidence and Analytics directorate.
"As well as looking at evidence generation for pharmaceuticals, the GetReal Institute will have an opportunity to expand its remit to incorporate medical technologies and digital health interventions. These are two areas where NICE shares a mutual interest of better data and research.
“Our role within the GetReal Institute will enhance our ability to work with like-minded organisations to tackle challenges in the area of real world evidence which need unified support in order to ensure the needs of patients are met in 2021 and beyond.”
The GetReal Institute is a not-for-profit organisation and is based in the Netherlands.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
A refreshed Evidence Standards Framework for Digital Health Technologies and an increased focus on digital health for NICE11/05/2021 14:15:00
Two exciting developments which will accelerate NICE’s efforts to deliver innovation to the health and care system faster.
Avelumab not recommended as a maintenance treatment of urothelial cancer after platinum-based chemotherapy07/05/2021 16:15:00
NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy.
NICE announces more people eligible for nusinersen following review of Managed Access Agreement04/05/2021 14:15:00
NICE has today (4 May 2021) announced that more people with the rare genetic disorder spinal muscular atrophy (SMA) are to benefit from nusinersen (also called Spinraza and made by Biogen) following a review of data collected as part of the Managed Access Agreement (MAA).
New draft guidance aims to achieve fairer outcomes for looked-after children and young people30/04/2021 16:15:00
Looked after children and young people should be considered ‘one of their own’ by carers, in order to help them to reach their full potential, new NICE draft guidelines say
Thousands with high cholesterol set to benefit from new treatment on the NHS28/04/2021 14:15:00
Thousands of people with high cholesterol will soon have access to a new treatment option on the NHS as a result of final NICE guidance published today (28 April 2021).
NICE publishes updated clinical guideline on the diagnosis and management of atrial fibrillation28/04/2021 09:15:00
NICE yesterday (27 April 2021) published its updated guideline on the diagnosis and management of atrial fibrillation (AF).
NICE recommends new treatment for rare blood disorder23/04/2021 11:15:00
Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft guidance from NICE.
Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia21/04/2021 13:05:00
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
NICE draft guidance provides Cancer Drugs Fund first in Europe access to new treatment option for advanced breast cancer21/04/2021 11:15:00
NICE yesterday (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) for treating a type of breast cancer called HER2 positive breast cancer which can’t be surgically removed or which has spread to other parts of the body.